2023-04-27 10:14:00 ET
- Eli Lilly ( LLY ) is returning the rights to atopic dermatitis candidate rezpegaldesleukin (REZPEG) back to Nektar Therapeutics ( NASDAQ: NKTR ).
- Earlier in April, Nektar ( NKTR ) said it would move REZPEG forward this year in a phase 2 trial for mild-to-severe atopic dermatitis.
- Phase 1 data presented by Lilly ( LLY ) before indicated REZPEG showed dose-dependent improvemen t over placebo for key efficacy measures.
- Seeking Alpha's Quant Rating has rated Nektar ( NKTR ) a strong sell since Feb. 16.
For further details see:
Nektar regains rights to atopic dermatitis candidate from Eli Lilly